ClinicalTrials.gg
CompletedNCT00696384Updated Jan 4, 2012Results posted

A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

A Phase 3 interventional study of Azilsartan medoxomil and Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications. in Hypertension, sponsored by Takeda. Completed at 45 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-04.

Primary conditionEssential HypertensionRegistry: HypertensionReclassifiedWhy we changed it
Registry
Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Essential Hypertension
Why
  1. The study's title name Essential Hypertension, a narrower term within Hypertension.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
418
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing azilsartan medoxomil in Essential Hypertension — none open to participants now, none under way, none of them phase 3. azilsartan medoxomil · Essential Hypertension.

Enrollment
10th of 11
418 · median 837
Started
2007
with 2 others
Phase 3
10 of 11
none open now
Registered
1st of 11
by date
Lead sponsor
11 of 11
Takeda

Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, this one is the 10th largest by enrollment, is one of 3 that started in 2007, is one of 10 in phase 3, and was the 1st registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

None of the 11 studies testing azilsartan medoxomil in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →

About azilsartan medoxomil

azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing azilsartan medoxomil in Essential Hypertension as a file.
02

Study summary

The purpose of this study is to determine the long term safety and tolerability of azilsartan medoxomil, once daily (QD), in participants with Essential Hypertension.

Read the detailed description

Hypertension affects approximately 50 million individuals in the United States. As the population ages, the prevalence of hypertension will continue to increase if broad and effective preventive measures are not implemented. According to the World Health Organization, hypertension is the most common attributable cause of preventable death in developed nations, as uncontrolled hypertension greatly increases the risk of cardiovascular disease, cerebrovascular disease, and renal failure.

A major component of blood pressure regulation is the renin-angiotensin-aldosterone system, a system of hormone-mediated feedback interactions that results in the relaxation or constriction of blood vessels in response to various stimuli. Angiotensin II, a polypeptide hormone, is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme as part of the renin-angiotensin-aldosterone system. AII is the principal pressor agent of the renin-angiotensin-aldosterone system with a myriad of effects on the cardiovascular system and on electrolyte homeostasis. Two receptors for angiotensin II have been identified. Angiotensin II type 1 (AT1) receptors are located predominantly in vascular smooth muscle, where activation by angiotensin II results in vasoconstriction, hypertrophic proliferation, and inflammation. In contrast, stimulation of angiotensin II type 2 (AT2) receptors by angiotensin II results in vasodilation, antiproliferative effects, and other effects that are opposite from those of AT1 receptor stimulation.

Drugs that modulate the renin-angiotensin-aldosterone system are used commonly worldwide for the treatment of hypertension. Of these, some block the synthesis of angiotensin II by inhibiting angiotensin-converting enzyme inhibitors, while others inhibit the action of angiotensin II by binding directly to the AT1 receptor (angiotensin II receptor blockers), thereby allowing blood vessels to dilate, resulting in a reduction in blood pressure. The effects of angiotensin II receptor blockers on other conditions in which the renin-angiotensin-aldosterone system plays a significant role, such as congestive heart failure, post-myocardial infarction management, and diabetic nephropathy, also are being investigated.

Takeda Global Research \& Development Center, Inc. is developing TAK-491 (azilsartan medoxomil) to treat mild to moderate essential hypertension. Nonclinical studies have indicated that azilsartan medoxomil is an antagonist of the AT1 receptor subtype.

This study consists of 2 phases. The first phase will be a 26-week, open-label, multicenter phase to evaluate the safety and tolerability of TAK-491 in participants with essential hypertension. Investigators were instructed to manage participants according to a protocol-specified treatment algorithm to achieve target blood pressure. All participants who completed the open-label phase then were randomized into a 6-week double-blind, placebo-controlled (azilsartan medoxomil [maintained at the final dose from the open-label phase] or placebo, in addition to their current other antihypertensive medications including chlorthalidone, as applicable) reversal phase to evaluate maintenance/durability of azilsartan medoxomil -mediated blood pressure reduction, as well as potential rebound following the cessation of azilsartan medoxomil.

Study participation is anticipated to be about 8.5 Months. Multiple procedures will occur at each visit which may include fasting, blood collection, urine collection, vital signs including sitting and standing blood pressure and pulse, body height and weight, physical examinations and electrocardiograms.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Essential Hypertension
  • Cardiovascular Disease
  • High Blood Pressure
  • Drug Therapy
04

In context

Essential Hypertension Reclassified

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

This study's enrollment of 418 is above the median of 144 across 407 interventional studies indexed under Essential Hypertension.

Browse Essential Hypertension studies →

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Compared within Essential Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has essential hypertension (diastolic blood pressure ≥ 95mm Hg and ≤ 119 mm Hg. For participants with diabetes or chronic kidney disease diastolic blood pressure must be ≥ 85 mm Hg and ≤ to 109 mm Hg.
  2. Female participant is not of (eg, sterilized, ).
  3. Female participants of childbearing potential who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.
  4. Clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis) are within the reference range for the testing laboratory unless the results are deemed not for inclusion into this study by the investigator.

Exclusion criteria

Exclusion Criteria

  1. Systolic blood pressure greater than 185 mm Hg.
  2. Is required to take or intends to continue taking any disallowed medication, any prescription medication, herbal treatment or over-the counter medication that may interfere with evaluation of the study medication, including:
  3. Is hypersensitive to AII receptor blockers.
  4. Recent history (within the last 6 months) of myocardial infarction, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, cerebrovascular accident, or .
  5. History of moderate to severe heart failure or hypertensive encephalopathy.
  6. Has cardiac conduction defects (eg, third-degree atrioventricular block, sick sinus syndrome).
  7. Has secondary hypertension of any etiology.
  8. Known or suspected unilateral or bilateral renal artery stenosis.
  9. Has severe renal dysfunction or disease (based on calculated \< 30 mL/min/1.73 m2) at Screening.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
418 participants (actual)

Study arms

  • Experimental
    Azilsartan Medoxomil QD-Open Label Phase (Baseline - Week 26)

    Drug: Azilsartan medoxomil

  • Experimental
    Azilsartan Medoxomil QD - Double-Blind Phase (Week 26-32)

    Drug: Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.

  • Placebo comparator
    Placebo QD - Double-Blind Phase (Week 26- 32)

    Drug: Placebo

Interventions

  • All subjects initiated azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks, force-titrated to 80 mg, tablets, orally, once daily. After Week 8, chlorthalidone, 25 mg, tablets, orally, once daily as needed and other antihypertensive medications as needed to achieve target blood pressure (defined as \<140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) and \<130/80 mm Hg for participants with diabetes or CKD) for up to 26 weeks. Study medication could have been up-titrated only after the subject had been at the previous dose level for a minimum of 2 weeks. Study medication could only have been up- or down-titrated by 1 dose level per scheduled or unscheduled visit.

    Also known as: TAK-491, Edarbi

  • DrugAzilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.

    Drug page: Azilsartan medoxomil

    Azilsartan medoxomil at the final dose received during the open-label phase: (20 mg, 40 mg or 80 mg), tablets, orally, once daily with or without chlorthalidone 25 mg, tablets, orally once daily and other non-ARB antihypertensive medications (if currently taking), for 6 weeks/Week 32.

    Also known as: TAK-491, Edarbi

  • DrugPlacebo

    Azilsartan medoxomil placebo-matching tablets, orally, once daily with or without chlorthalidone 25 mg or other non-ARB antihypertensive (if currently taking), tablets, orally, once daily for 6 weeks/Week 32.

07

What researchers measure

Primary outcomes

  1. Change From Double-blind Baseline (Week 26) in Sitting Clinic Diastolic Blood Pressure to Week 32

    The change in sitting clinic diastolic blood pressure measured at final visit or week 32 from Double-blind Baseline/Week 26. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements. Each participant's blood pressure at the Final Visit/Week 26 of the open-label phase represented their Baseline blood pressure for the double-blind reversal phase.

    Time frame: Double-blind Baseline (Week 26) and Week 32.

Secondary outcomes

  1. Change From Double-blind Baseline (Week 26) in Sitting Clinic Systolic Blood Pressure to Week 32

    The change in sitting clinic systolic blood pressure measured at final visit or week 32 from Double-blind Baseline/Week 26.. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements. Each participant's blood pressure at the Final Visit/Week 26 of the open-label phase represented their Baseline blood pressure for the double-blind reversal phase.

    Time frame: Double-blind Baseline (Week 26) and Week 32.

  2. Change From Open Label Baseline (Week 0) in Sitting Clinic Diastolic Blood Pressure to Week 26

    The change from baseline in sitting clinic diastolic blood pressure measured at final visit or week 26.

    Time frame: Baseline and Week 26.

  3. Change From Open Label Baseline (Week 0) in Sitting Clinic Systolic Blood Pressure to Week 26

    The change from baseline in sitting clinic systolic blood pressure measured at final visit or week 26.

    Time frame: Baseline and Week 26.

  4. Number of Participants With Adverse Events During the Open-Label Phase

    Treatment-emergent adverse events defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after last dose of study drug, or within 30 days after the last dose of study drug for serious adverse event (SAE). A SAE is defined as any untoward medical occurrence that either results in death; is life-threatening; requires hospitalization; results in persistent or significant disability/incapacity; leads to a congenital anomaly/birth defect; or is an important medical event.

    Time frame: Baseline to Week 26

  5. Number of Participants With Adverse Events in the Double-Blind Baseline Phase

    Treatment-emergent adverse events defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after last dose of study drug, or within 30 days after the last dose of study drug for SAE. A SAE is defined as any untoward medical occurrence that either results in death; is life-threatening; requires hospitalization; results in persistent or significant disability/incapacity; leads to a congenital anomaly/birth defect; or is an important medical event.

    Time frame: Double-blind Baseline/Week 26 to Week 32

08

Results

Posted Jan 4, 2012

Participant flow

Participants enrolled at 51 investigative sites in Argentina, Mexico and the United States from 22 June 2007 to 08 May 2009.

Open Label Phase
Participant flow — Open Label Phase
MilestoneAzilsartan Medoxomil QD - Open Label PhaseAzilsartan Medoxomil QD - Double-Blind Reversal PhasePlacebo QD - Double-Blind Reversal Phase
Started41800
Completed29900
Not completed11900
Withdrew: Adverse event2700
Withdrew: Protocol violation1800
Withdrew: Lost to follow-up2400
Withdrew: Withdrawal by subject3700
Withdrew: Other600
Withdrew: Lack of efficacy300
Withdrew: Physician decision400
Double Blind Phase
Participant flow — Double Blind Phase
MilestoneAzilsartan Medoxomil QD - Open Label PhaseAzilsartan Medoxomil QD - Double-Blind Reversal PhasePlacebo QD - Double-Blind Reversal Phase
Started0148151
Completed0137145
Not completed0116
Withdrew: Adverse event022
Withdrew: Lost to follow-up021
Withdrew: Withdrawal by subject043
Withdrew: Lack of efficacy010
Withdrew: Physician decision020

Outcome measures

PrimaryChange From Double-blind Baseline (Week 26) in Sitting Clinic Diastolic Blood Pressure to Week 32

The change in sitting clinic diastolic blood pressure measured at final visit or week 32 from Double-blind Baseline/Week 26. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements. Each participant's blood pressure at the Final Visit/Week 26 of the open-label phase represented their Baseline blood pressure for the double-blind reversal phase.

Time frame:
Double-blind Baseline (Week 26) and Week 32.
Reported as:
Least squares mean · mmHg
Change From Double-blind Baseline (Week 26) in Sitting Clinic Diastolic Blood Pressure to Week 32
mmHgAzilsartan Medoxomil QD - Double Blind Reversal PhasePlacebo QD - Double Blind Reversal Phase
Change From Double-blind Baseline (Week 26) in Sitting Clinic Diastolic Blood Pressure to Week 320.14 ± 0.7267.92 ± 0.712
Statistical analysis
  • Azilsartan Medoxomil QD - Double Blind Reversal Phase vs Placebo QD - Double Blind Reversal Phase · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Includes participants with both a double-blind baseline and postbaseline value.) · Mean difference (final values): -7.78 · 95% CI -9.78 to -5.78
SecondaryChange From Double-blind Baseline (Week 26) in Sitting Clinic Systolic Blood Pressure to Week 32

The change in sitting clinic systolic blood pressure measured at final visit or week 32 from Double-blind Baseline/Week 26.. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements. Each participant's blood pressure at the Final Visit/Week 26 of the open-label phase represented their Baseline blood pressure for the double-blind reversal phase.

Time frame:
Double-blind Baseline (Week 26) and Week 32.
Reported as:
Least squares mean · mmHg
Change From Double-blind Baseline (Week 26) in Sitting Clinic Systolic Blood Pressure to Week 32
mmHgAzilsartan Medoxomil QD - Double Blind Reversal PhasePlacebo QD - Double Blind Reversal Phase
Change From Double-blind Baseline (Week 26) in Sitting Clinic Systolic Blood Pressure to Week 320.59 ± 1.12112.97 ± 1.098
Statistical analysis
  • Azilsartan Medoxomil QD - Double Blind Reversal Phase vs Placebo QD - Double Blind Reversal Phase · ANCOVA · p = <0.001 (Postbaseline P-value was from ANCOVA with terms for treatment (as a factor) and baseline value (as a covariate). Includes participants with both a double-blind baseline and postbaseline value.) · Mean difference (final values): -12.38 · 95% CI -15.47 to -9.29
SecondaryChange From Open Label Baseline (Week 0) in Sitting Clinic Diastolic Blood Pressure to Week 26

The change from baseline in sitting clinic diastolic blood pressure measured at final visit or week 26.

Time frame:
Baseline and Week 26.
Reported as:
Mean · mmHg
Change From Open Label Baseline (Week 0) in Sitting Clinic Diastolic Blood Pressure to Week 26
mmHgAzilsartan Medoxomil QD - Open Label Phase
Change From Open Label Baseline (Week 0) in Sitting Clinic Diastolic Blood Pressure to Week 26-15.76 ± 11.912
SecondaryChange From Open Label Baseline (Week 0) in Sitting Clinic Systolic Blood Pressure to Week 26

The change from baseline in sitting clinic systolic blood pressure measured at final visit or week 26.

Time frame:
Baseline and Week 26.
Reported as:
Mean · mmHg
Change From Open Label Baseline (Week 0) in Sitting Clinic Systolic Blood Pressure to Week 26
mmHgAzilsartan Medoxomil QD - Open Label Phase
Change From Open Label Baseline (Week 0) in Sitting Clinic Systolic Blood Pressure to Week 26-23.01 ± 20.657
SecondaryNumber of Participants With Adverse Events During the Open-Label Phase

Treatment-emergent adverse events defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after last dose of study drug, or within 30 days after the last dose of study drug for serious adverse event (SAE). A SAE is defined as any untoward medical occurrence that either results in death; is life-threatening; requires hospitalization; results in persistent or significant disability/incapacity; leads to a congenital anomaly/birth defect; or is an important medical event.

Time frame:
Baseline to Week 26
Reported as:
Number · participants
Number of Participants With Adverse Events During the Open-Label Phase
participantsAzilsartan Medoxomil QD - Open Label Phase
Serious Adverse Events8
Treatment Emergent Adverse Events226
SecondaryNumber of Participants With Adverse Events in the Double-Blind Baseline Phase

Treatment-emergent adverse events defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug through 14 days after last dose of study drug, or within 30 days after the last dose of study drug for SAE. A SAE is defined as any untoward medical occurrence that either results in death; is life-threatening; requires hospitalization; results in persistent or significant disability/incapacity; leads to a congenital anomaly/birth defect; or is an important medical event.

Time frame:
Double-blind Baseline/Week 26 to Week 32
Reported as:
Number · participants
Number of Participants With Adverse Events in the Double-Blind Baseline Phase
participantsAzilsartan Medoxomil QD - Double Blind Reversal PhasePlacebo QD - Double Blind Reversal Phase
Serious Adverse Events01
Treatment Emergent Adverse Events4238

Adverse events

Collected over Treatment-emergent adverse events are adverse events that started after the first dose of double-blind study drug and no more than 14 days (or 30 days for a serious adverse event) after the last dose of double-blind study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Azilsartan Medoxomil QD - Open Label—8/418 (1.9%)60/418 (14.4%)
Azilsartan Medoxomil QD - Double-Blind Reversal Phase—0/148 (0%)5/148 (3.4%)
Placebo QD - Double-Blind Reversal Phase—1/151 (0.7%)8/151 (5.3%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventAzilsartan Medoxomil QD - Open LabelAzilsartan Medoxomil QD - Double-Blind Reversal PhasePlacebo QD - Double-Blind Reversal Phase
Hypertensive crisisVascular disorders0/4180/1481/151
Acute coronary syndromeCardiac disorders1/4180/1480/151
Diabetic retinopathyEye disorders1/4180/1480/151
Eye haemorrhageEye disorders1/4180/1480/151
PancreatitisGastrointestinal disorders1/4180/1480/151
Upper gastrointestinal haemorrhageGastrointestinal disorders1/4180/1480/151
Hip fractureInjury, poisoning and procedural complications1/4180/1480/151
DehydrationMetabolism and nutrition disorders1/4180/1480/151
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/4180/1480/151
ConvulsionNervous system disorders1/4180/1480/151
Most frequent other events
Most frequent other events
EventAzilsartan Medoxomil QD - Open LabelAzilsartan Medoxomil QD - Double-Blind Reversal PhasePlacebo QD - Double-Blind Reversal Phase
DizzinessNervous system disorders36/4183/1483/151
HeadacheNervous system disorders30/4185/1488/151

Baseline characteristics

Age, Customized
Age, Customized(participants)Azilsartan Medoxomil QD - Open Label Phase
<45 years89
Between 45 and 64 years287
≥ 65 years42
Age, Customized
Age, Customized(percentage of participants)Azilsartan Medoxomil QD - Open Label Phase
<45 years21.3
Between 45 and 64 years68.7
≥ 65 years10.0
Sex/Gender, Customized
Sex/Gender, Customized(participants)Azilsartan Medoxomil QD - Open Label Phase
Female210
Male208
09

Study locations

45 sites
  • Huntsville, Alabama, United States
  • Chandler, Arizona, United States
  • Mesa, Arizona, United States
  • Tempe, Arizona, United States
  • Los Gatos, California, United States
  • Sacramento, California, United States
  • Tustin, California, United States
  • Westlake Village, California, United States
  • Colorado Springs, Colorado, United States
  • Wheat Ridge, Colorado, United States
  • Melbourne, Florida, United States
  • Pembroke Pines, Florida, United States
  • Augusta, Georgia, United States
  • South Bend, Indiana, United States
  • Auburn, Maine, United States
  • Marlborough, Massachusetts, United States
  • Chelsea, Michigan, United States
  • St. Louis, Missouri, United States
  • Trenton, New Jersey, United States
  • Rochester, New York, United States
  • Burlington, North Carolina, United States
  • Wilmington, North Carolina, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Carlisle, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Mt. Pleasant, South Carolina, United States
  • San Antonio, Texas, United States
  • Norfolk, Virginia, United States
  • Lakewood, Washington, United States
  • Renton, Washington, United States
  • Madison, Wisconsin, United States
  • Berazategui, Buenos Aires, Argentina
  • Pilar, Buenos Aires, Argentina
  • Cordoba, Argentina
  • Salta, Argentina
  • Leon, Guanajuato, Mexico
  • Guadalajara, Jalisco, Mexico
  • Cuernavaca, Morelos, Mexico
  • Rosario, Santa Fe, Mexico
  • Tampico, Tamaulipas, Mexico
  • Durango, Mexico
  • Mexico DF, Mexico
  • Puebla, Mexico
10

References and documents

Publications

  • Kipnes MS, Handley A, Lloyd E, Barger B, Roberts A. Safety, tolerability, and efficacy of azilsartan medoxomil with or without chlorthalidone during and after 8 months of treatment for hypertension. J Clin Hypertens (Greenwich). 2015 Mar;17(3):183-92. doi: 10.1111/jch.12474. Epub 2015 Jan 24. PubMed 25619410 ↗
11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2008
First posted
Jun 12, 2008
Start
Jun 2007
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results first posted
Jan 4, 2012
Last update
Jan 4, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00696384
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jun 12, 2008
Start date
Jun 2007
Primary completion
Apr 2009
Completion
Apr 2009
Results posted
Jan 4, 2012
Last update
Jan 4, 2012

Study contacts

VP Clinical Science Strategy
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azilsartan medoxomil

Start the discussion